Clinical trial
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With…
NCT00499252 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00499252 |
|---|---|
| Title | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| Official title | A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma |
| Intervention type | Drug |
| Interventions | Paclitaxel Albumin-Stabilized Nanoparticle Formulation |
| Enrollment | 51 |
| Start date | Jun 1, 2007 |
| Primary completion | Jul 1, 2011 |
| First posted | Jul 11, 2007 |
| Last update posted | Jan 11, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: